News Tenax trounced by phase 3 heart failure readout Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.
News Sobi adds rare lymphoma drug with $580m Innate tie-up Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.
R&D Clinical Trials Round-Up: May and June 2026 May and June delivered a plethora of clinical trial updates. In the build-up to ASCO in June, our inbox was overflowing with oncology trial results.
News Moderna starts first trial of its Bundibugyo Ebola vaccine Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus, as the outbreak in DRC gathers pace.
News MSD records one hit, one miss with TL1A drug tulisokibart MSD's tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but has failed a study in rare lung disorder SSc-ILD.
R&D A practical route through regulatory uncertainty in clinical... Organisations must remain agile and decisive across global portfolios, anticipating regulatory changes before they create clinical trial delays.
News England close to eliminating hep C thanks to treatment drive England is on track to be one of the first countries in the world to eliminate hepatitis C, thanks to a national diagnosis and treatment programme.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.